Meeting
2016 ASCO Annual Meeting
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study.
Authors
Anna Maria Di Giacomo
Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy
Anna Maria Di Giacomo , Alessia Covre , Pietro Taverna , Sandra Coral , Giovanni Amato , Harold N. Keer , James N. Lowder , Diana Giannarelli , Mohammad Azab , Michele Maio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02608437
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS9595)
DOI
10.1200/JCO.2016.34.15_suppl.TPS9595
Abstract #
TPS9595
Poster Bd #
198a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.
First Author: Anna Maria Di Giacomo
Poster
2013 ASCO Annual Meeting
Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.
First Author: Yvonne M. Saenger
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A novel humanized anti-CTLA-4 antibody compared to ipilimumab in preclinical studies.
First Author: Qian Shi